· Earnings watch · TLX
Telix Pharmaceuticals Limited (TLX) enters earnings week with weak relative strength
The oncology radiopharmaceuticals developer has recovered over 12 weeks, but its shorter-term tape remains uneven before the June 18 report.
Telix Pharmaceuticals Limited (TLX) closed at $9.56 in the latest weekly market data, rising 2.8% for the week as investors look toward its scheduled June 18 earnings report. The company is expected to report for the fiscal quarter ended March 31, with an estimate of -$0.01 per share.
The setup is mixed. Shares are still down -9.5% over four weeks, while the 12-week return stands at 9.3%; volume was 1.09 times the 13-week average. Market Dynamics shows modest confirmation at 0.44, but Relative Strength remains weak at -21.3. The weekly price path over 52 weeks provides longer-term context rather than live intraday action.